Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.

World Health Organization. Global Arbovirus Initiative https://www.who.int/news-room/events/detail/2022/03/31/default-calendar/global-arbovirus-initiative (2022).

Balakrishnan, V. S. WHO launches global initiative for arboviral diseases. Lancet Microbe 3, e407 (2022).

pubmed: 35659901 pmcid: 9159734 doi: 10.1016/S2666-5247(22)00130-6

Roiz, D. et al. The rising global economic costs of Aedes and Aedes-borne diseases. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-2679030/v1 (2023).

Longbottom, J. et al. Aedes albopictus invasion across Africa: the time is now for cross-country collaboration and control. Lancet Glob. Health 11, e623–e628 (2023).

pubmed: 36841255 doi: 10.1016/S2214-109X(23)00046-3

Suhrbier, A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat. Rev. Rheumatol. 15, 597–611 (2019).

pubmed: 31481759 doi: 10.1038/s41584-019-0276-9

Casades-Marti, L. et al. Risk factors for exposure of wild birds to West Nile virus in a gradient of wildlife-livestock interaction. Pathogens 12, 83 (2023).

pubmed: 36678431 pmcid: 9864363 doi: 10.3390/pathogens12010083

Read, A. J. et al. Clinical and epidemiological features of West Nile virus equine encephalitis in New South Wales, Australia, 2011. Aust. Vet. J. 97, 133–143 (2019).

pubmed: 31025323 doi: 10.1111/avj.12810

Mulvey, P. et al. The ecology and evolution of Japanese encephalitis virus. Pathogens 10, 1534 (2021).

pubmed: 34959489 pmcid: 8704921 doi: 10.3390/pathogens10121534

Pham, D. et al. Emergence of Japanese encephalitis in Australia: a diagnostic perspective. Pathology 54, 669–677 (2022).

pubmed: 35995617 doi: 10.1016/j.pathol.2022.07.001

Pedersen, C. E. Jr., Robinson, D. M. & Cole, F. E. Jr. Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana. Am. J. Epidemiol. 95, 490–496 (1972).

pubmed: 4401801 doi: 10.1093/oxfordjournals.aje.a121416

Coates, E. E. et al. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Lancet Infect. Dis. 22, 1210–1220 (2022).

pubmed: 35568049 pmcid: 9329218 doi: 10.1016/S1473-3099(22)00052-4

Li, B., Wang, H. & Liang, G. Getah virus (alphavirus): an emerging, spreading zoonotic virus. Pathogens 11, 945 (2022).

pubmed: 36015065 pmcid: 9416625 doi: 10.3390/pathogens11080945

Thorarinsson, R. et al. Effects of a DNA and multivalent oil-adjuvanted vaccines against pancreas disease in Atlantic salmon (Salmo salar) challenged with salmonid alphavirus subtype 3. Fish Shellfish Immunol. Rep. 3, 100063 (2022).

pubmed: 36419608 pmcid: 9680106 doi: 10.1016/j.fsirep.2022.100063

Harris, E. FDA approves first chikungunya vaccine. JAMA 330, 2241–2241 (2023).

pubmed: 38019508

World Health Organization. Disease Outbreak News: Western Equine Encephalitis in Argentina https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON499 (2023).

Yan, K. et al. A yellow fever virus 17D infection and disease mouse model used to evaluate a chimeric Binjari-yellow fever virus vaccine. Vaccines 8, 368 (2020).

pubmed: 32660106 pmcid: 7564786 doi: 10.3390/vaccines8030368

Wu, B., Qi, Z. & Qian, X. Recent advancements in mosquito-borne flavivirus vaccine development. Viruses 15, 813 (2023).

pubmed: 37112794 pmcid: 10143207 doi: 10.3390/v15040813

Koopmans, M., de Lamballerie, X., Jaenisch, T. & Consortium, Z. I. Familiar barriers still unresolved — a perspective on the Zika virus outbreak research response. Lancet Infect. Dis. 19, e59–e62 (2019).

pubmed: 30420230 doi: 10.1016/S1473-3099(18)30497-3

Ritchie, S. et al. In: Innovative Strategies for Vector Control (eds Koenraadt, C. J. M., Spitzen, J. & Takken, W.) 58-89 (Wageningen Academic Publishers, 2021).

World Health Organization. Call for Public Consultation-development of Target Product Profiles (TPPs) for Wolbachia infected Aedes aegypti Population Replacement Intervention https://www.who.int/news-room/articles-detail/call-for-public-consultation-development-target-product-profiles-wolbachia-infected-aedes-aegypti-population-replacement-intervention (2021).

Ant, T. H., Mancini, M. V., McNamara, C. J., Rainey, S. M. & Sinkins, S. P. Wolbachia-virus interactions and arbovirus control through population replacement in mosquitoes. Pathog. Glob. Health 117, 245–258 (2023).

pubmed: 36205550 doi: 10.1080/20477724.2022.2117939

Possas, C. et al. Vaccine innovation for dengue, chikungunya, zika and yellow fever: accelerating global development agenda and partnerships in post-COVID era. Vacc. Res. 2, 1–17 (2022).

Pierson, T. C. & Diamond, M. S. The continued threat of emerging flaviviruses. Nat. Microbiol. 5, 796–812 (2020).

pubmed: 32367055 pmcid: 7696730 doi: 10.1038/s41564-020-0714-0

Zimmerman, O., Holmes, A. C., Kafai, N. M., Adams, L. J. & Diamond, M. S. Entry receptors — the gateway to alphavirus infection. J. Clin. Invest. 133, e165307 (2023).

pubmed: 36647825 pmcid: 9843064 doi: 10.1172/JCI165307

Pan, Y. et al. Flaviviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Front. Immunol. 13, 829433 (2022).

pubmed: 35154151 pmcid: 8835115 doi: 10.3389/fimmu.2022.829433

Hobson-Peters, J. et al. A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus. Sci. Transl. Med. 11, eaax7888 (2019).

pubmed: 31826984 doi: 10.1126/scitranslmed.aax7888

Abbo, S. R. et al. Comparative efficacy of Mayaro virus-like particle vaccines produced in insect or mammalian cells. J. Virol. 97, e0160122 (2023).

pubmed: 36883812 doi: 10.1128/jvi.01601-22

Castilho, L. R., Mattos, N. R., Abreu, W. S. & Gutarra, M. L. E. Virus-like particles (VLPs) as important tools for flavivirus vaccine development. Biologics 2, 226–242 (2022).

doi: 10.3390/biologics2040018

Bennett, S. R. et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect. Dis. 22, 1343–1355 (2022).

pubmed: 35709798 doi: 10.1016/S1473-3099(22)00226-2

Adams, C. et al. Structure and neutralization mechanism of a human antibody targeting a complex epitope on Zika virus. PLoS Pathog. 19, e1010814 (2023).

pubmed: 36626401 pmcid: 9870165 doi: 10.1371/journal.ppat.1010814

Salem, G. M. et al. Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus. Commun. Biol. 7, 15 (2024).

pubmed: 38267569 pmcid: 10808242 doi: 10.1038/s42003-023-05661-w

Tsuji, I. et al. Somatic hypermutation and framework mutations of variable region contribute to anti-Zika virus-specific monoclonal antibody binding and function. J. Virol. 96, e0007122 (2022).

pubmed: 35575481 doi: 10.1128/jvi.00071-22

Kim, A. S. & Diamond, M. S. A molecular understanding of alphavirus entry and antibody protection. Nat. Rev. Microbiol. 21, 396–407 (2023).

pubmed: 36474012 doi: 10.1038/s41579-022-00825-7

Raju, S. et al. A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci. Transl. Med. 15, eade8273 (2023).

pubmed: 37196061 pmcid: 10562830 doi: 10.1126/scitranslmed.ade8273

Hasan, S. S. et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat. Commun. 8, 14722 (2017).

pubmed: 28300075 pmcid: 5356071 doi: 10.1038/ncomms14722

Zhang, S. et al. A human antibody neutralizes different flaviviruses by using different mechanisms. Cell Rep. 31, 107584 (2020).

pubmed: 32348755 doi: 10.1016/j.celrep.2020.107584

Fox, J. M. et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163, 1095–1107 (2015).

pubmed: 26553503 pmcid: 4659373 doi: 10.1016/j.cell.2015.10.050

Sharma, A. et al. The epitope arrangement on flavivirus particles contributes to Mab C10’s extraordinary neutralization breadth across Zika and dengue viruses. Cell 184, 6052–6066 (2021). An excellent example illustrating how antibodies neutralize flaviviruses.

pubmed: 34852239 pmcid: 8724787 doi: 10.1016/j.cell.2021.11.010

Roux, K. H., Strelets, L. & Michaelsen, T. E. Flexibility of human IgG subclasses. J. Immunol. 159, 3372–3382 (1997).

pubmed: 9317136 doi: 10.4049/jimmunol.159.7.3372

Wrigley, N. G., Brown, E. B. & Skehel, J. J. Electron microscopic evidence for the axial rotation and inter-domain flexibility of the Fab regions of immunoglobulin G. J. Mol. Biol. 169, 771–774 (1983).

pubmed: 6631952 doi: 10.1016/S0022-2836(83)80170-3

Chu, T. H., Patz, E. F. Jr. & Ackerman, M. E. Coming together at the hinges: therapeutic prospects of IgG3. mAbs 13, 1882028 (2021).

pubmed: 33602056 pmcid: 7899677 doi: 10.1080/19420862.2021.1882028

Kam, Y. W. et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J. Infect. Dis. 205, 1147–1154 (2012).

pubmed: 22389226 pmcid: 3295607 doi: 10.1093/infdis/jis033

Zepeda, O. et al. Antibody immunity to Zika virus among young children in a flavivirus-endemic area in Nicaragua. Viruses 15, 796 (2023).

pubmed: 36992504 pmcid: 10052059 doi: 10.3390/v15030796

Lim, X. X. et al. Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics. Cell 184, 6067–6080.e13 (2021).

pubmed: 34852238 doi: 10.1016/j.cell.2021.11.009

Stiasny, K., Medits, I., Rossbacher, L. & Heinz, F. X. Impact of structural dynamics on biological functions of flaviviruses. FEBS J. 290, 1973–1985 (2023).

pubmed: 35246954 doi: 10.1111/febs.16419

Gould, C. V. et al. Transmission of yellow fever vaccine virus through blood transfusion and organ transplantation in the USA in 2021: report of an investigation. Lancet Microbe 4, e711–e721 (2023). A cautionary tale for the transmission of live-attenuated virus vaccines, from an example of the use of metagenomic next-generation sequencing for diagnosis.

pubmed: 37544313 doi: 10.1016/S2666-5247(23)00170-2

Strauss, J. H. & Strauss, E. G. Recombination in alphaviruses. Semin. Virol. 8, 85–94 (1997).

doi: 10.1006/smvy.1997.0115

Seligman, S. J. & Gould, E. A. Live flavivirus vaccines: reasons for caution. Lancet 363, 2073–2075 (2004).

pubmed: 15207960 doi: 10.1016/S0140-6736(04)16459-3

Brault, A. C. et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat. Genet. 39, 1162–1166 (2007).

pubmed: 17694056 pmcid: 2291521 doi: 10.1038/ng2097

Dietrich, E. A., Ong, Y. T., Stovall, J. L., Dean, H. & Huang, C. Y. Limited transmission potential of Takeda’s tetravalent dengue vaccine candidate by Aedes albopictus. Am. J. Trop. Med. Hyg. 97, 1423–1427 (2017).

pubmed: 28820715 pmcid: 5817759 doi: 10.4269/ajtmh.17-0185

de Miranda, R. M. et al. Neotropical sylvatic mosquitoes and Aedes aegypti are not competent to transmit 17DD attenuated yellow fever virus from vaccinated viremic new world non-human primates. Viruses 14, 2231 (2022).

pubmed: 36298786 pmcid: 9611963 doi: 10.3390/v14102231

Wang, X., Usama, A., Huanchun, C., Cao, S. & Ye, J. Biological determinants perpetuating the transmission dynamics of mosquito-borne flaviviruses. Emerg. Microbes Infect. 12, 2212812 (2023).

pubmed: 37158598 pmcid: 10274526 doi: 10.1080/22221751.2023.2212812

Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116–125 (2009).

pubmed: 19029902 doi: 10.1038/ni.1688

Prow, N. A. et al. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nat. Commun. 9, 1230 (2018).

pubmed: 29581442 pmcid: 5964325 doi: 10.1038/s41467-018-03662-6

Zhang, T. et al. Research progress of aluminum phosphate adjuvants and their action mechanisms. Pharmaceutics 15, 1756 (2023).

pubmed: 37376204 pmcid: 10305650 doi: 10.3390/pharmaceutics15061756

Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109 (2023).

pubmed: 36911719 pmcid: 9998920 doi: 10.3389/fimmu.2023.1043109

Strezova, A. et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect. Dis. 9, ofac485 (2022).

pubmed: 36299530 pmcid: 9588150 doi: 10.1093/ofid/ofac485

Weaver, S. C., Pfeffer, M., Marriott, K., Kang, W. & Kinney, R. M. Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks. Am. J. Trop. Med. Hyg. 60, 441–448 (1999).

pubmed: 10466974 doi: 10.4269/ajtmh.1999.60.441

Nguyen, W. et al. Arthritogenic alphavirus vaccines: serogrouping versus cross-protection in mouse models. Vaccines 8, 209 (2020).

pubmed: 32380760 pmcid: 7349283 doi: 10.3390/vaccines8020209

Wijewardana, V., Ulbert, S. & Cattoli, G. Editorial: Irradiation technologies for vaccine development. Front. Immunol. 13, 1075335 (2023).

pubmed: 36700215 pmcid: 9869150 doi: 10.3389/fimmu.2022.1075335

Sundaram, A. K. et al. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates. Vaccine 38, 3313–3320 (2020).

pubmed: 32184032 doi: 10.1016/j.vaccine.2020.03.008

Adam, A. et al. Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models. Emerg. Microbes Infect. 10, 305–316 (2021).

pubmed: 33539255 pmcid: 7919884 doi: 10.1080/22221751.2021.1886598

The University of Queensland Australia. Vaccine to Protect Pigs from Japanese Encephalitis Virus https://www.uq.edu.au/news/article/2023/02/vaccine-protect-pigs-japanese-encephalitis-virus (2023).

Shaw, C. A. et al. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine 41, 3898–3906 (2023). One of the first mRNA vaccine trials for an alphavirus, showing that 79% of vaccine recipients had measurable neutralizing antibody responses to CHIKV 1 year after a two-dose vaccine regimen.

pubmed: 37210308 doi: 10.1016/j.vaccine.2023.04.064

Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect. Dis. 23, 621–633 (2023). Some of the first mRNA vaccine trials for a flavivirus showing that responses to ZIKV persisted for up to a year; collection of data beyond 13 months is planned.

pubmed: 36682364 doi: 10.1016/S1473-3099(22)00764-2

Prow, N. A. et al. The vaccinia virus based sementis copenhagen vector vaccine against Zika and chikungunya is immunogenic in non-human primates. NPJ Vaccines 5, 44 (2020).

pubmed: 32550013 pmcid: 7265471 doi: 10.1038/s41541-020-0191-8

Konishi, E. et al. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188, 714–720 (1992).

pubmed: 1585642 doi: 10.1016/0042-6822(92)90526-U

Bollman, B. et al. An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection. NPJ Vaccines 8, 58 (2023).

pubmed: 37080988 pmcid: 10119314 doi: 10.1038/s41541-023-00656-4

Rzymski, P., Szuster-Ciesielska, A., Dzieciatkowski, T., Gwenzi, W. & Fal, A. mRNA vaccines: the future of prevention of viral infections? J. Med. Virol. 95, e28572 (2023).

pubmed: 36762592 doi: 10.1002/jmv.28572

Evans, J. P. et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci. Transl. Med. 14, eabn8057 (2022). This study describes in detail a key potential limitation for mRNA vaccine technology in terms of waning antibody titres over a relatively short timeframe.

pubmed: 35166573 doi: 10.1126/scitranslmed.abn8057

Wieten, R. W. et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS One 11, e0149871 (2016).

pubmed: 26977808 pmcid: 4792480 doi: 10.1371/journal.pone.0149871

O’Connor, M. A. et al. A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. PLoS Pathog. 19, e1011298 (2023).

pubmed: 37075079 pmcid: 10150980 doi: 10.1371/journal.ppat.1011298

Comes, J. D. G., Pijlman, G. P. & Hick, T. A. H. Rise of the RNA machines — self-amplification in mRNA vaccine design. Trends Biotechnol. 41, 1417–1429 (2023).

pubmed: 37328401 doi: 10.1016/j.tibtech.2023.05.007

McGee, J. E. et al. Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA. Preprint at bioRxiv https://doi.org/10.1101/2023.09.15.557994 (2023). For current mRNA vaccines, N-methyl pseudouridine is used in place of uridine to reduce type I interferon responses that inhibit translation; this modification does not support self-amplifying RNA but this study identifies other modifications that do.

Piras-Douce, F. et al. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques. Vaccine 41, 1457–1470 (2023).

pubmed: 36702693 doi: 10.1016/j.vaccine.2022.11.051

Schneider, M. et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 401, 2138–2147 (2023). A pivotal phase III trial for IXCHIQ, leading the way to approval via the accelerated approval pathway; the first approved CHIKV vaccine.

pubmed: 37321235 pmcid: 10314240 doi: 10.1016/S0140-6736(23)00641-4

Matangkasombut, P. et al. Dengue viremia kinetics in asymptomatic and symptomatic infection. Int. J. Infect. Dis. 101, 90–97 (2020).

pubmed: 32992011 doi: 10.1016/j.ijid.2020.09.1446

Wressnigg, N. et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect. Dis. 20, 1193–1203 (2020).

pubmed: 32497524 doi: 10.1016/S1473-3099(20)30238-3

Roques, P. et al. Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera. JCI Insight 7, e160173 (2022). This study describes a novel approach to demonstrate the protective capacity of vaccine-induced antibodies via passive transfer of vaccine-recipient sera to non-human primates that were then challenged with CHIKV.

pubmed: 35700051 pmcid: 9431671 doi: 10.1172/jci.insight.160173

Konishi, E. et al. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol. 73, 5527–5534 (1999).

pubmed: 10364301 pmcid: 112610 doi: 10.1128/JVI.73.7.5527-5534.1999

Hugo, L. E., Prow, N. A., Tang, B., Devine, G. & Suhrbier, A. Chikungunya virus transmission between Aedes albopictus and laboratory mice. Parasit. Vectors 9, 555 (2016).

pubmed: 27760560 pmcid: 5069946 doi: 10.1186/s13071-016-1838-1

Lambrechts, L. et al. Direct mosquito feedings on dengue-2 virus-infected people reveal dynamics of human infectiousness. PLoS Negl. Trop. Dis. 17, e0011593 (2023).

pubmed: 37656759 pmcid: 10501553 doi: 10.1371/journal.pntd.0011593

Hou, J., Ye, W. & Chen, J. Current development and challenges of tetravalent live-attenuated dengue vaccines. Front. Immunol. 13, 840104 (2022).

pubmed: 35281026 pmcid: 8907379 doi: 10.3389/fimmu.2022.840104

de Castro Ferreira, C. et al. The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Rev. Vaccines 17, 79–90 (2018).

doi: 10.1080/14760584.2018.1406800

Laera, D., HogenEsch, H. & O’Hagan, D. T. Aluminum adjuvants — ‘back to the future’. Pharmaceutics 15, 1884 (2023).

pubmed: 37514070 pmcid: 10383759 doi: 10.3390/pharmaceutics15071884

Burrack, K. S., Montgomery, S. A., Homann, D. & Morrison, T. E. CD8

pubmed: 25488988 doi: 10.4049/jimmunol.1401833

Grubor-Bauk, B. et al. NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice. Sci. Adv. 5, eaax2388 (2019).

pubmed: 31844662 pmcid: 6905874 doi: 10.1126/sciadv.aax2388

Castilow, E. M. & Varga, S. M. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 3, 445–454 (2008).

pubmed: 19057653 pmcid: 2593094 doi: 10.2217/17460794.3.5.445

Iwata-Yoshikawa, N. et al. A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. Sci. Adv. 8, eabh3827 (2022).

pubmed: 34995117 pmcid: 8741184 doi: 10.1126/sciadv.abh3827

Doherty, T. M. & Rook, G. Progress and hindrances in tuberculosis vaccine development. Lancet 367, 947–949 (2006).

pubmed: 16546547 doi: 10.1016/S0140-6736(06)68389-X

Stone, E. T. & Pinto, A. K. T cells in tick-borne flavivirus encephalitis: a review of current paradigms in protection and disease pathology. Viruses 15, 958 (2023).

pubmed: 37112938 pmcid: 10146733 doi: 10.3390/v15040958

Garber, C. et al. T cells promote microglia-mediated synaptic elimination and cognitive dysfunction during recovery from neuropathogenic flaviviruses. Nat. Neurosci. 22, 1276–1288 (2019).

pubmed: 31235930 pmcid: 6822175 doi: 10.1038/s41593-019-0427-y

Kehn-Hall, K. & Bradfute, S. B. Understanding host responses to equine encephalitis virus infection: implications for therapeutic development. Expert Rev. Anti Infect. Ther. 20, 1551–1566 (2022).

pubmed: 36305549 doi: 10.1080/14787210.2022.2141224

Poo, Y. S. et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl. Trop. Dis. 8, e3354 (2014).

pubmed: 25474568 pmcid: 4256279 doi: 10.1371/journal.pntd.0003354

Reagin, K. L. & Funk, K. E. The role of antiviral CD8

pubmed: 35810534 pmcid: 9489663 doi: 10.1016/j.conb.2022.102603

Saxena, V., Mathur, A., Krishnani, N. & Dhole, T. N. An insufficient anti-inflammatory cytokine response in mouse brain is associated with increased tissue pathology and viral load during Japanese encephalitis virus infection. Arch. Virol. 153, 283–292 (2008).

pubmed: 18074098 doi: 10.1007/s00705-007-1098-7

Lee, J., Woodruff, M. C., Kim, E. H. & Nam, J. H. Knife’s edge: balancing immunogenicity and reactogenicity in mRNA vaccines. Exp. Mol. Med. 55, 1305–1313 (2023).

pubmed: 37430088 pmcid: 10394010 doi: 10.1038/s12276-023-00999-x

Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T

pubmed: 32998157 doi: 10.1038/s41586-020-2814-7

Farmer, J. F. & Suhrbier, A. Interpreting paired serology for Ross River virus and Barmah Forest virus diseases. Aust. J. Gen. Pract. 48, 645–649 (2019).

pubmed: 31476825 doi: 10.31128/AJGP-02-19-4845

Wressnigg, N. et al. An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial. Clin. Vaccin. Immunol. 22, 267–273 (2015).

doi: 10.1128/CVI.00546-14

Nasveld, P. E. et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum. Vaccin. 6, 1038–1046 (2010).

pubmed: 21150279 pmcid: 3060383 doi: 10.4161/hv.6.12.13057

Salje, H. et al. Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. Nat. Med. 27, 1395–1400 (2021).

pubmed: 34168334 pmcid: 8364868 doi: 10.1038/s41591-021-01392-9

Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007).

pubmed: 17989383 doi: 10.1056/NEJMoa066092

Ernst, D. Long-Term Immunogenicity, Effectiveness Observed with HPV Vaccine Gardasil 9 https://www.empr.com/home/news/long-term-immunogenicity-effectiveness-observed-with-hpv-vaccine-gardasil-9/ (2023).

Yu, D., Walker, L. S. K., Liu, Z., Linterman, M. A. & Li, Z. Targeting T(FH) cells in human diseases and vaccination: rationale and practice. Nat. Immunol. 23, 1157–1168 (2022).

pubmed: 35817844 doi: 10.1038/s41590-022-01253-8

Corrado, M. & Pearce, E. L. Targeting memory T cell metabolism to improve immunity. J. Clin. Invest. 132, e148546 (2022).

pubmed: 34981777 pmcid: 8718135 doi: 10.1172/JCI148546

Tran, Q. M. et al. Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling. Vaccine 41, 182–192 (2023).

pubmed: 36424258 doi: 10.1016/j.vaccine.2022.11.028

Chen, G. L. et al. Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial. JAMA 323, 1369–1377 (2020).

pubmed: 32286643 pmcid: 7156994 doi: 10.1001/jama.2020.2477

Pereira, S. S. et al. NS1-based ELISA test efficiently detects dengue infections without cross-reactivity with Zika virus. Int. J. Infect. Dis. 112, 202–204 (2021).

pubmed: 34555500 doi: 10.1016/j.ijid.2021.09.009

Edelman, R. et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62, 681–685 (2000).

pubmed: 11304054 doi: 10.4269/ajtmh.2000.62.681

Hills, S. Evidence to Recommendations for Chikungunya Vaccine use Among Adult Travelers https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/02-Chikungunya-Hills-508.pdf (2023).

Waickman, A. T. et al. Evolution of inflammation and immunity in a dengue virus 1 human infection model. Sci. Transl. Med. 14, eabo5019 (2022).

pubmed: 36288280 doi: 10.1126/scitranslmed.abo5019

Barnes, M. V. C., Mandla, A., Smith, E., Maskuniitty, M. & Openshaw, P. J. M. Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunother. Adv. 3, ltad024 (2023).

pubmed: 38020312 pmcid: 10640868 doi: 10.1093/immadv/ltad024

Cooper, M. M., Loiseau, C., McCarthy, J. S. & Doolan, D. L. Human challenge models: tools to accelerate the development of malaria vaccines. Expert Rev. Vaccines 18, 241–251 (2019).

pubmed: 30732492 doi: 10.1080/14760584.2019.1580577

Paixao, E. S. et al. Mortality from congenital Zika syndrome — nationwide cohort study in Brazil. N. Engl. J. Med. 386, 757–767 (2022).

pubmed: 35196428 pmcid: 7612437 doi: 10.1056/NEJMoa2101195

Yin, P. et al. Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions in vitro and in vivo. Nat. Microbiol. 8, 1653–1667 (2023).

pubmed: 37591996 pmcid: 10956380 doi: 10.1038/s41564-023-01449-0

Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649 (2012).

pubmed: 22535666 doi: 10.1182/blood-2012-01-380121

Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23, 381–396 (2023).

pubmed: 36536068 doi: 10.1038/s41577-022-00813-1

European Medicines Agency. Assessment Report: Qdenga https://www.ema.europa.eu/en/documents/assessment-report/qdenga-epar-public-assessment-report_en.pdf (2022).

Dias, A. G. Jr. et al. Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. Sci. Transl. Med. 14, eabm3151 (2022). This study describes a systems serology approach illustrating a role for Fc receptor engagement in protection against symptomatic DENV infection.

pubmed: 35767652 pmcid: 10115655 doi: 10.1126/scitranslmed.abm3151

Loos, C. et al. Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design. NPJ Vaccines 8, 34 (2023).

pubmed: 36890168 pmcid: 9992919 doi: 10.1038/s41541-023-00613-1

O’Connor, D. The omics strategy: the use of systems vaccinology to characterize immune responses to childhood immunization. Expert Rev. Vaccines 21, 1205–1214 (2022).

pubmed: 35786291 doi: 10.1080/14760584.2022.2093193

Hagan, T. et al. Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses. Nat. Immunol. 23, 1788–1798 (2022).

pubmed: 36316475 pmcid: 9869360 doi: 10.1038/s41590-022-01328-6

Hazlewood, J. E. et al. Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures. PLoS Pathog. 17, e1009215 (2021).

pubmed: 33439897 pmcid: 7837487 doi: 10.1371/journal.ppat.1009215

Kosoy, G. & Miller, B. L. Two decades of arrayed imaging reflectometry for sensitive, high-throughput biosensing. Biosensors 13, 870 (2023).

pubmed: 37754104 pmcid: 10526495 doi: 10.3390/bios13090870

Liu, X. et al. Metabolomics acts as a powerful tool for comprehensively evaluating vaccines approved under emergency: a CoronaVac retrospective study. Front. Immunol. 14, 1168308 (2023).

pubmed: 37520533 pmcid: 10375237 doi: 10.3389/fimmu.2023.1168308

Kannan, S., Subbaram, K. & Faiyazuddin, M. In A Handbook of Artificial Intelligence in Drug Delivery (eds Philip, A., Shahiwala, A., Rashid, M. & Faiyazuddin, M.) 467-486 (Academic Press, 2023).

Carvalho, D. O. et al. Transgene-induced cell death following dengue-2 virus infection in Aedes aegypti. Sci. Rep. 13, 5958 (2023).

pubmed: 37045866 pmcid: 10097671 doi: 10.1038/s41598-023-32895-9

Spinner, S. A. M. et al. New self-sexing Aedes aegypti strain eliminates barriers to scalable and sustainable vector control for governments and communities in dengue-prone environments. Front. Bioeng. Biotechnol. 10, 975786 (2022).

pubmed: 36394032 pmcid: 9650594 doi: 10.3389/fbioe.2022.975786

Waltz, E. Biotech firm announces results from first US trial of genetically modified mosquitoes. Nature 604, 608–609 (2022).

pubmed: 35437323 doi: 10.1038/d41586-022-01070-x

Lee, W. S., Webster, J. A., Madzokere, E. T., Stephenson, E. B. & Herrero, L. J. Mosquito antiviral defense mechanisms: a delicate balance between innate immunity and persistent viral infection. Parasit. Vectors 12, 165 (2019).

pubmed: 30975197 pmcid: 6460799 doi: 10.1186/s13071-019-3433-8

Samuel, G. H., Adelman, Z. N. & Myles, K. M. Antiviral immunity and virus-mediated antagonism in disease vector mosquitoes. Trends Microbiol. 26, 447–461 (2018).

pubmed: 29395729 pmcid: 5910197 doi: 10.1016/j.tim.2017.12.005

Perveen, N. et al. Host-pathogen interaction in arthropod vectors: lessons from viral infections. Front. Immunol. 14, 1061899 (2023).

pubmed: 36817439 pmcid: 9929866 doi: 10.3389/fimmu.2023.1061899

Schuster, S., Miesen, P. & van Rij, R. P. Antiviral RNAi in insects and mammals: parallels and differences. Viruses 11, 448 (2019).

pubmed: 31100912 pmcid: 6563508 doi: 10.3390/v11050448

Utarini, A. et al. Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. N. Engl. J. Med. 384, 2177–2186 (2021). This study reports an impressive result for Wolbachia intervention, having a protective efficacy of 77.1% against dengue.

pubmed: 34107180 pmcid: 8103655 doi: 10.1056/NEJMoa2030243

World Health Organization Vector Control Advisory Group. Eighteenth Meeting of the WHO Vector Control Advisory Group, Meeting report, 24–26 April 2023 https://apps.who.int/iris/rest/bitstreams/1523233/retrieve (2023).

Zug, R. & Hammerstein, P. Wolbachia and the insect immune system: what reactive oxygen species can tell us about the mechanisms of Wolbachia-host interactions. Front. Microbiol. 6, 1201 (2015).

pubmed: 26579107 pmcid: 4621438 doi: 10.3389/fmicb.2015.01201

Wang, Z., Yong, H., Zhang, S., Liu, Z. & Zhao, Y. Colonization resistance of symbionts in their insect hosts. Insects 14, 594 (2023).

pubmed: 37504600 pmcid: 10380809 doi: 10.3390/insects14070594

Fattouh, N., Cazevieille, C. & Landmann, F. Wolbachia endosymbionts subvert the endoplasmic reticulum to acquire host membranes without triggering ER stress. PLoS Negl. Trop. Dis. 13, e0007218 (2019).

pubmed: 30893296 pmcid: 6426186 doi: 10.1371/journal.pntd.0007218

Kaur, R. et al. Living in the endosymbiotic world of Wolbachia: a centennial review. Cell Host Microbe 29, 879–893 (2021).

pubmed: 33945798 pmcid: 8192442 doi: 10.1016/j.chom.2021.03.006

Shropshire, J. D., Leigh, B. & Bordenstein, S. R. Symbiont-mediated cytoplasmic incompatibility: what have we learned in 50 years? eLife 9, e61989 (2020).

pubmed: 32975515 pmcid: 7518888 doi: 10.7554/eLife.61989

Zheng, R. et al. Holobiont perspectives on tripartite interactions among microbiota, mosquitoes, and pathogens. ISME J. 17, 1143–1152 (2023).

pubmed: 37231184 doi: 10.1038/s41396-023-01436-7

Zhang, G., Hussain, M., O’Neill, S. L. & Asgari, S. Wolbachia uses a host microRNA to regulate transcripts of a methyltransferase, contributing to dengue virus inhibition in Aedes aegypti. Proc. Natl Acad. Sci. USA 110, 10276–10281 (2013).

pubmed: 23733960 pmcid: 3690878 doi: 10.1073/pnas.1303603110

Shin, S. W., Kokoza, V., Lobkov, I. & Raikhel, A. S. Relish-mediated immune deficiency in the transgenic mosquito Aedes aegypti. Proc. Natl Acad. Sci. USA 100, 2616–2621 (2003).

pubmed: 12594340 pmcid: 151389 doi: 10.1073/pnas.0537347100

Kokoza, V. et al. Engineering blood meal-activated systemic immunity in the yellow fever mosquito, Aedes aegypti. Proc. Natl Acad. Sci. USA 97, 9144–9149 (2000).

pubmed: 10908672 pmcid: 16836 doi: 10.1073/pnas.160258197

Bian, G., Shin, S. W., Cheon, H. M., Kokoza, V. & Raikhel, A. S. Transgenic alteration of Toll immune pathway in the female mosquito Aedes aegypti. Proc. Natl Acad. Sci. USA 102, 13568–13573 (2005).

pubmed: 16157887 pmcid: 1224621 doi: 10.1073/pnas.0502815102

Franz, A. W. et al. Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified Aedes aegypti. Proc. Natl Acad. Sci. USA 103, 4198–4203 (2006).

pubmed: 16537508 pmcid: 1449670 doi: 10.1073/pnas.0600479103

Reid, W. R., Olson, K. E. & Franz, A. W. E. Current effector and gene-drive developments to engineer arbovirus-resistant Aedes aegypti (Diptera: Culicidae) for a sustainable population replacement strategy in the field. J. Med. Entomol. 58, 1987–1996 (2021).

pubmed: 33704462 pmcid: 8421695 doi: 10.1093/jme/tjab030

Buchman, A. et al. Engineered resistance to Zika virus in transgenic Aedes aegypti expressing a polycistronic cluster of synthetic small RNAs. Proc. Natl Acad. Sci. USA 116, 3656–3661 (2019).

pubmed: 30723148 pmcid: 6397566 doi: 10.1073/pnas.1810771116

Buchman, A. et al. Broad dengue neutralization in mosquitoes expressing an engineered antibody. PLoS Pathog. 16, e1008103 (2020).

pubmed: 31945137 pmcid: 6964813 doi: 10.1371/journal.ppat.1008103

Mishra, P., Furey, C., Balaraman, V. & Fraser, M. J. Antiviral hammerhead ribozymes are effective for developing transgenic suppression of chikungunya virus in Aedes aegypti mosquitoes. Viruses 8, 163 (2016).

pubmed: 27294950 pmcid: 4926183 doi: 10.3390/v8060163

Williams, A. E., Franz, A. W. E., Reid, W. R. & Olson, K. E. Antiviral effectors and gene drive strategies for mosquito population suppression or replacement to mitigate arbovirus transmission by Aedes aegypti. Insects 11, 52 (2020).

pubmed: 31940960 pmcid: 7023000 doi: 10.3390/insects11010052

Bier, E. Gene drives gaining speed. Nat. Rev. Genet. 23, 5–22 (2022).

pubmed: 34363067 doi: 10.1038/s41576-021-00386-0

Cobb, M. Gene drives could fight malaria and other global killers but might have unintended consequences. Scientific American https://go.nature.com/3Ty3JFY (13 January 2023).

National Gene Technology Scheme. Draft National Gene Drive Policy Guide https://go.nature.com/3xcbOIK (2023).

Riabinina, O., Quinn, M. & Whitehead, J. P. Genetic toolbox approaches in mosquitoes. Cold Spring Harb. Protoc. https://doi.org/10.1101/pdb.top107691 (2022).

doi: 10.1101/pdb.top107691 pubmed: 35960628

World Health Organization. Guidance Framework for Testing Genetically Modified Mosquitoes https://iris.who.int/handle/10665/341370 (2021).

James, S. L., Dass, B. & Quemada, H. Regulatory and policy considerations for the implementation of gene drive-modified mosquitoes to prevent malaria transmission. Transgenic Res. 32, 17–32 (2023).

pubmed: 36920721 pmcid: 10102045 doi: 10.1007/s11248-023-00335-z

Patterson, E. I., Villinger, J., Muthoni, J. N., Dobel-Ober, L. & Hughes, G. L. Exploiting insect-specific viruses as a novel strategy to control vector-borne disease. Curr. Opin. Insect Sci. 39, 50–56 (2020).

pubmed: 32278312 pmcid: 7302987 doi: 10.1016/j.cois.2020.02.005

Hall, R. A. et al. Commensal viruses of mosquitoes: host restriction, transmission, and interaction with arboviral pathogens. Evol. Bioinform. Online 12, 35–44 (2016).

pubmed: 28096646

Olmo, R. P. et al. Mosquito vector competence for dengue is modulated by insect-specific viruses. Nat. Microbiol. 8, 135–149 (2023). This study provides a mechanistic explanation for how insect-specific viruses can increase the transmission of dengue.

pubmed: 36604511 doi: 10.1038/s41564-022-01289-4

Zakrzewski, M. et al. Mapping the virome in wild-caught Aedes aegypti from Cairns and Bangkok. Sci. Rep. 8, 4690 (2018).

pubmed: 29549363 pmcid: 5856816 doi: 10.1038/s41598-018-22945-y

Feng, Y. et al. A time-series meta-transcriptomic analysis reveals the seasonal, host, and gender structure of mosquito viromes. Virus Evol. 8, veac006 (2022).

pubmed: 35242359 pmcid: 8887699 doi: 10.1093/ve/veac006

Romo, H., Kenney, J. L., Blitvich, B. J. & Brault, A. C. Restriction of Zika virus infection and transmission in Aedes aegypti mediated by an insect-specific flavivirus. Emerg. Microbes Infect. 7, 181 (2018).

pubmed: 30429457 pmcid: 6235874 doi: 10.1038/s41426-018-0180-4

Goenaga, S. et al. Potential for co-infection of a mosquito-specific flavivirus, Nhumirim virus, to block West Nile virus transmission in mosquitoes. Viruses 7, 5801–5812 (2015).

pubmed: 26569286 pmcid: 4664984 doi: 10.3390/v7112911

Baidaliuk, A. et al. Cell-fusing agent virus reduces arbovirus dissemination in Aedes aegypti mosquitoes in vivo. J. Virol. 93, e00705-19 (2019).

pubmed: 31243123 pmcid: 6714787 doi: 10.1128/JVI.00705-19

Joseph, R. E., Bozic, J., Werling, K. L., Urakova, N. & Rasgon, J. L. Eilat virus (EILV) causes superinfection exclusion against West NILE virus (WNV) in a strain specific manner in Culex tarsalis mosquitoes. Preprint at bioRxiv https://doi.org/10.1101/2023.05.25.542294 (2023).

doi: 10.1101/2023.05.25.542294 pubmed: 38187633 pmcid: 10769265

Koh, C., Henrion-Lacritick, A., Frangeul, L. & Saleh, M. C. Interactions of the insect-specific palm Creek virus with Zika and Chikungunya viruses in Aedes mosquitoes. Microorganisms 9, 1652 (2021).

pubmed: 34442731 pmcid: 8402152 doi: 10.3390/microorganisms9081652

Tan, L., Zhang, Y., Kim, D. Y. & Li, R. Insect-specific chimeric viruses potentiated antiviral responses and inhibited pathogenic alphavirus growth in mosquito cells. Microbiol. Spectr. 11, e0361322 (2023).

pubmed: 36511715 doi: 10.1128/spectrum.03613-22

Prince, B. C., Walsh, E., Torres, T. Z. B. & Rückert, C. Recognition of arboviruses by the mosquito immune system. Biomolecules 13, 1159 (2023).

pubmed: 37509194 pmcid: 10376960 doi: 10.3390/biom13071159

McLean, B. J. et al. A novel insect-specific flavivirus replicates only in Aedes-derived cells and persists at high prevalence in wild Aedes vigilax populations in Sydney, Australia. Virology 486, 272–283 (2015).

pubmed: 26519596 doi: 10.1016/j.virol.2015.07.021

Ratcliffe, N. A. et al. Overview of paratransgenesis as a strategy to control pathogen transmission by insect vectors. Parasit. Vectors 15, 112 (2022).

pubmed: 35361286 pmcid: 8969276 doi: 10.1186/s13071-021-05132-3

Wang, S. & Jacobs-Lorena, M. Genetic approaches to interfere with malaria transmission by vector mosquitoes. Trends Biotechnol. 31, 185–193 (2013).

pubmed: 23395485 pmcid: 3593784 doi: 10.1016/j.tibtech.2013.01.001

Fofana, A. et al. The strategy of paratransgenesis for the control of malaria transmission. Front. Trop. Dis. 3, 867104 (2022).

doi: 10.3389/fitd.2022.867104

Wang, S. et al. Fighting malaria with engineered symbiotic bacteria from vector mosquitoes. Proc. Natl Acad. Sci. USA 109, 12734–12739 (2012).

pubmed: 22802646 pmcid: 3412027 doi: 10.1073/pnas.1204158109

Wang, S. et al. Driving mosquito refractoriness to Plasmodium falciparum with engineered symbiotic bacteria. Science 357, 1399–1402 (2017).

pubmed: 28963255 pmcid: 9793889 doi: 10.1126/science.aan5478

Patterson, E. I. et al. Negeviruses reduce replication of alphaviruses during coinfection. J. Virol. 95, e0043321 (2021).

pubmed: 33952645 doi: 10.1128/JVI.00433-21

Liu, P. et al. Development of non-defective recombinant densovirus vectors for microRNA delivery in the invasive vector mosquito, Aedes albopictus. Sci. Rep. 6, 20979 (2016).

pubmed: 26879823 pmcid: 4754678 doi: 10.1038/srep20979

World Mosquito Program. Annual Review https://www.worldmosquitoprogram.org/sites/default/files/2023-06/WMP-AnnualReview-2022.pdf (2022).

US Food & Drug Administration. FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus (2023).

Götte, B., Liu, L. & McInerney, G. M. The enigmatic alphavirus non-structural protein 3 (nsP3) revealing its secrets at last. Viruses 10, 105 (2018).

pubmed: 29495654 pmcid: 5869498 doi: 10.3390/v10030105

Roques, P. et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2, e83527 (2017).

pubmed: 28352649 pmcid: 5358498 doi: 10.1172/jci.insight.83527

Burton, D. R. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat. Rev. Immunol. 23, 720–734 (2023).

pubmed: 37069260 doi: 10.1038/s41577-023-00858-w

Powell, L. A. et al. Human mAbs broadly protect against arthritogenic alphaviruses by recognizing conserved elements of the Mxra8 receptor-binding site. Cell Host Microbe 28, 699–711 (2020).

pubmed: 32783883 pmcid: 7666055 doi: 10.1016/j.chom.2020.07.008

Basore, K. et al. Cryo-EM structure of Chikungunya virus in complex with the Mxra8 receptor. Cell 177, 1725–1737 (2019).

pubmed: 31080061 pmcid: 7227486 doi: 10.1016/j.cell.2019.04.006

Ma, H. et al. The low-density lipoprotein receptor promotes infection of multiple encephalitic alphaviruses. Nat. Commun. 15, 246 (2024).

pubmed: 38172096 pmcid: 10764363 doi: 10.1038/s41467-023-44624-x

Xie, S., Zhang, H., Liang, Z., Yang, X. & Cao, R. AXL, an important host factor for DENV and ZIKV replication. Front. Cell Infect. Microbiol. 11, 575346 (2021).

pubmed: 33954117 pmcid: 8092360 doi: 10.3389/fcimb.2021.575346

Zhou, Q. F. et al. Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Proc. Natl Acad. Sci. USA 117, 27637–27645 (2020).

pubmed: 33087569 pmcid: 7959576 doi: 10.1073/pnas.2008051117

Williamson, L. E. et al. Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies. Proc. Natl Acad. Sci. USA 120, e2213690120 (2023).

pubmed: 36961925 pmcid: 10068833 doi: 10.1073/pnas.2213690120

Kafai, N. M. et al. Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge. J. Exp. Med. 219, e20212532 (2022).

pubmed: 35297953 pmcid: 9195047 doi: 10.1084/jem.20212532

Ramjag, A. et al. A high-throughput screening assay to identify inhibitory antibodies targeting alphavirus release. Virol. J. 19, 170 (2022).

pubmed: 36309730 pmcid: 9617529 doi: 10.1186/s12985-022-01906-y

Williamson, L. E. et al. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Cell 184, 4430–4446 (2021).

pubmed: 34416147 pmcid: 8418820 doi: 10.1016/j.cell.2021.07.033

Malekshahi, Z. et al. Interference of the Zika virus E-protein with the membrane attack complex of the complement system. Front. Immunol. 11, 569549 (2020).

pubmed: 33193347 pmcid: 7655927 doi: 10.3389/fimmu.2020.569549

Earnest, J. T. et al. The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies. Cell Rep. 35, 108962 (2021).

pubmed: 33826892 pmcid: 8055377 doi: 10.1016/j.celrep.2021.108962

Chen, X. et al. Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. J. Immunol. Methods 488, 112900 (2021).

pubmed: 33075363 doi: 10.1016/j.jim.2020.112900

Piliponsky, A. M., Acharya, M. & Shubin, N. J. Mast cells in viral, bacterial, and fungal infection immunity. Int. J. Mol. Sci. 20, 2851 (2019).

pubmed: 31212724 pmcid: 6627964 doi: 10.3390/ijms20122851

Schwedler, J. L. et al. Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function. mAbs 16, 2297451 (2024).

pubmed: 38170638 pmcid: 10766394 doi: 10.1080/19420862.2023.2297451

Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 4593–4595 (2021).

pubmed: 34416148 pmcid: 8375150 doi: 10.1016/j.cell.2021.07.027

Mangalmurti, N. & Hunter, C. A. Cytokine storms: understanding COVID-19. Immunity 53, 19–25 (2020). This article introduces the concept of protective inflammation, an area that is increasingly being characterized for COVID-19 but remains understudied for arbovirus infections.

pubmed: 32610079 pmcid: 7321048 doi: 10.1016/j.immuni.2020.06.017

Long, K. M. & Heise, M. T. Protective and pathogenic responses to Chikungunya virus. Infect. Curr. Trop. Med. Rep. 2, 13–21 (2015).

pubmed: 26366337 doi: 10.1007/s40475-015-0037-z

Foy, B. H., Sundt, T. M., Carlson, J. C. T., Aguirre, A. D. & Higgins, J. M. Human acute inflammatory recovery is defined by co-regulatory dynamics of white blood cell and platelet populations. Nat. Comm. 13, 4705 (2022).

doi: 10.1038/s41467-022-32222-2

Yang, X. et al. Antibody-dependent enhancement: “Evil” antibodies favorable for viral infections. Viruses 14, 1739 (2022).

pubmed: 36016361 pmcid: 9412366 doi: 10.3390/v14081739

Martinez-Vega, R. A., Carrasquila, G., Luna, E. & Ramos-Castaneda, J. ADE and dengue vaccination. Vaccine 35, 3910–3912 (2017).

pubmed: 28623027 doi: 10.1016/j.vaccine.2017.06.004

Mallapaty, S. Dengue vaccine poised for roll-out but safety concerns linger. Nature 611, 434–435 (2022).

pubmed: 36352113 doi: 10.1038/d41586-022-03546-2

Thomas, S. J. Is new dengue vaccine efficacy data a relief or cause for concern? NPJ Vaccines 8, 55 (2023).

pubmed: 37061527 pmcid: 10105158 doi: 10.1038/s41541-023-00658-2

Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123–1128 (2020).

pubmed: 32855339 pmcid: 8274975 doi: 10.1126/science.abb6143

Modhiran, N. et al. A broadly protective antibody that targets the flavivirus NS1 protein. Science 371, 190–194 (2021).

pubmed: 33414219 doi: 10.1126/science.abb9425

Guirakhoo, F., Domi, A. & Paul, N. Methods for generating a ZIKV immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein. US Patent 11638750 B2 (2020).

Suhrbier, A. & La Linn, M. Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol. 24, 165–168 (2003).

pubmed: 12697441 doi: 10.1016/S1471-4906(03)00065-6

Taylor, A. et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol. Rev. 268, 340–364 (2015).

pubmed: 26497532 pmcid: 7165974 doi: 10.1111/imr.12367

Garcia-Nicolas, O. et al. A Japanese encephalitis virus vaccine inducing antibodies strongly enhancing in vitro infection is protective in pigs. Viruses 9, 124 (2017).

pubmed: 28531165 pmcid: 5454436 doi: 10.3390/v9050124

Kubinski, M. et al. Tick-borne encephalitis virus: a quest for better vaccines against a virus on the rise. Vaccines 8, 451 (2020).

pubmed: 32806696 pmcid: 7564546 doi: 10.3390/vaccines8030451

Simon-Loriere, E. & Schwartz, O. Towards SARS-CoV-2 serotypes? Nat. Rev. Microbiol. 20, 187–188 (2022).

pubmed: 35181769 pmcid: 8855751 doi: 10.1038/s41579-022-00708-x

Nakayama, E. E. & Shioda, T. SARS-CoV-2 related antibody-dependent enhancement phenomena in vitro and in vivo. Microorganisms 11, 1015 (2023).

pubmed: 37110438 pmcid: 10145615 doi: 10.3390/microorganisms11041015

Gan, L., Chen, Y., Tan, J., Wang, X. & Zhang, D. Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. BMC Infect. Dis. 22, 742 (2022).

pubmed: 36123623 pmcid: 9483537 doi: 10.1186/s12879-022-07735-2

Powers, J. M. et al. Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein. PLoS Negl. Trop. Dis. 17, e0011154 (2023).

pubmed: 36913428 pmcid: 10036167 doi: 10.1371/journal.pntd.0011154

Salgado, R. et al. West Nile virus vaccination protects against Usutu virus disease in mice. Viruses 13, 2352 (2021).

pubmed: 34960621 pmcid: 8704473 doi: 10.3390/v13122352

Prow, N. A., Jimenez Martinez, R., Hayball, J. D., Howley, P. M. & Suhrbier, A. Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines. Expert Rev. Vaccines 17, 925–934 (2018).

pubmed: 30300041 doi: 10.1080/14760584.2018.1522255

Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Daniel J Rawle (DJ)

Leon E Hugo (LE)

Abigail L Cox (AL)

Gregor J Devine (GJ)

Andreas Suhrbier (A)

Classifications MeSH